News
Latest news from CHV and our portfolio companies
Featured News
PanTher Therapeutics (“PanTher” or the “Company”), a clinical-stage company redefining cancer treatment with therapeutics administered continuously and exclusively at the tumor site, today announced that it has concluded dosing in
Insights & Impacts: The latest from CHV
Epitel is developing a simplified, wearable EEG system, enabling both faster diagnosis and long-term monitoring
AtaCor Medical, Inc. announced today that it has completed enrollment in its initial acute Extravascular
Salt Lake City – December 15, 2021 – Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:
Partnership to include distribution of a children’s book with essential prenatal healthcare information and support
– Launch of First-in-Human Trial Follows Acceptance from Australian Human Research Ethics Committee – CAMBRIDGE,
Salt Lake City – September 13, 2021 – Sera Prognostics Inc., The Pregnancy Company™ (Nasdaq:
The entry of non-traditional funders – and the availability of non-traditional exits – has altered
Study demonstrates positive impact of the company’s PreTRM® test and treat strategy on improving neonatal
CHV invests exclusively in seed, Series A and Series B companies in the medtech space.
PTM-101 being developed to enhance therapeutic response with minimal side effects in patients with inoperable,